Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 6/20 | 0.40 |
| ▸ | NOS2 | P35228 | 6/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 4/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30045190 | 1.00 | PNMT (0.48) | PNMTENPP2LOXL2CA12CA1 | |
| Hydrochloric Acid SCHEMBL25370258 | 0.98 | HTR2C (0.47) | PNMTENPP2LOXL2CA12CA1 | |
| Hydrochloric Acid SCHEMBL30580209 | 0.98 | HTR2C (0.47) | PNMTENPP2LOXL2CA12CA1 | |
| SCHEMBL12908118 | 0.84 | MAOB (0.43) | PNMTENPP2LOXL2CA12CA1 | |
| SCHEMBL29829192 | 0.83 | TAAR1 (0.52) | PNMTLOXL2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL921005 | 0.82 | MAOB (0.44) | PNMTENPP2LOXL2HTR2CHTR2B | |
| SCHEMBL3838668 | 0.82 | CA12 (0.44) | CA12CA1CA2CA9CA14 | |
| SCHEMBL28241408 | 0.82 | ASIC3 (0.58) | PNMTENPP2LOXL2ASIC3NOS1 | |
| SCHEMBL580840 | 0.78 | LOXL2 (0.61) | PNMTENPP2LOXL2ALDH1A1 | |
| SCHEMBL2838377 | 0.78 | PNMT (0.48) | PNMTENPP2LOXL2ASIC3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. | 2021-04-01 | — | — | US | disclosed |
| WO-2019170086-A1 | ACYL-SUBSTITUTED OXAZINO-QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | 北京赛特明强医药科技有限公司 | 2019-09-12 | — | — | WO | disclosed |
| CN-106008475-B | Coumarin NEDD8 activating enzyme inhibitor | 南京工业大学 | 2019-01-22 | — | — | CN | disclosed |
| CN-106008475-A | Coumarin NEDD8 activating enzyme inhibitor | 南京工业大学 | 2016-10-12 | — | — | CN | disclosed |
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2015-10-08 | — | — | US | disclosed |
| CN-101535279-B | Quinazoline based egfr inhibitors containing a zinc binding moiety | CURIS INC | 2015-05-20 | — | — | CN | disclosed |
| US-9024024-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140221403-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8604044-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| CN-101641338-A | Multifunctional small molecules as antiproliferative agents | CURIS INC US | 2010-02-03 | — | — | CN | disclosed |
| CN-101535279-A | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS INC (US) | 2009-09-16 | — | — | CN | disclosed |
| EP-2061773-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-2061772-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | CURIS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033749-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | PNMT 3376/4885ENPP2 2421/4885LOXL2 3468/4885 |
| US-20140221403-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC5, ERBB4 | PNMT 3802/4885ENPP2 3479/4885LOXL2 2940/4885 |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | HDAC1, HDAC8, EGFR | PNMT 1054/4885ENPP2 2509/4885LOXL2 2403/4885 |
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | PNMT 2979/4885ENPP2 2140/4885LOXL2 4085/4885 |
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, ERBB4, HDAC5 | PNMT 3814/4885ENPP2 3520/4885LOXL2 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.